Janus Kinase Inhibitors

Janus Kinase Inhibitor

Arthritis, Rheumatoid

<section class="Section" data-sectioncode="34089-3"><a name="section-9"></a><h1>11 DESCRIPTION</h1>RINVOQ and RINVOQ LQ are formulated with upadacitinib, a JAK inhibitor. Upadacitinib has the following chemical name: (3S,4R)-3-Ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide hydrate (2:1). The strength of upadacitinib is based on anhydrous upadacitinib. The solubility of upadacitinib in water is 38 to less than 0.2 mg/mL across a pH range of 2 to 9 at 37 oC. Upadacitinib has a molecular weight of 389.38 g/mol and a molecular formula of C17H19F3N6O • ½ H2O. The chemical structure of upadacitinib is: <img alt="upadacitinib-chem-structure" src="rinvoq-01.jpg"/>RINVOQ 15 mg extended-release tablets for oral administration are purple, biconvex oblong, with dimensions of 14 x 8 mm, and debossed with ‘a15’ on one side. Each tablet contains the following inactive ingredients: colloidal silicon dioxide, ferrosoferric oxide, hypromellose, iron oxide red, magnesium stearate, mannitol, microcrystalline cellulose, polyvinyl alcohol, polyethylene glycol, talc, tartaric acid and titanium dioxide. RINVOQ 30 mg extended-release tablets for oral administration are red, biconvex oblong, with dimensions of 14 x 8 mm, and debossed with ‘a30’ on one side. Each tablet contains the following inactive ingredients: colloidal silicon dioxide, hypromellose, iron oxide red, magnesium stearate, mannitol, microcrystalline cellulose, polyvinyl alcohol, polyethylene glycol, talc, tartaric acid and titanium dioxide. RINVOQ 45 mg extended-release tablets for oral administration are yellow to mottled yellow, biconvex oblong, with dimensions of 14 x 8 mm, and debossed with ‘a45’ on one side. Each tablet contains the following inactive ingredients: colloidal silicon dioxide, hypromellose, iron oxide yellow, iron oxide red, magnesium stearate, mannitol, microcrystalline cellulose, polyvinyl alcohol, polyethylene glycol, talc, tartaric acid and titanium dioxide.RINVOQ LQ oral solution for oral administration is a 1 mg/mL clear, colorless to light yellow solution. Each 1 mL RINVOQ LQ contains 1 mg of upadacitinib as free base (equivalent to 1.02 mg upadacitinib hemihydrate) and the following inactive ingredients: citric acid anhydrous, purified water, sodium benzoate, sodium citrate dihydrate, and sucralose. </section>

Rinvoq

upadacitinib

24 HR upadacitinib 15 MG Extended Release Oral Tablet

24 HR upadacitinib 15 MG Extended Release Oral Tablet [Rinvoq]

24 HR upadacitinib 30 MG Extended Release Oral Tablet

24 HR upadacitinib 30 MG Extended Release Oral Tablet [Rinvoq]

24 HR upadacitinib 45 MG Extended Release Oral Tablet

24 HR upadacitinib 45 MG Extended Release Oral Tablet [Rinvoq]

upadacitinib 1 MG/ML Oral Solution

upadacitinib 1 MG/ML Oral Solution [Rinvoq]

BioPlus Specialty Pharmacy

Abraxane

Actemra

Afinitor

Avastin

Besponsa

Bosulif

Biktarvy

Braftovi

Cosentyx

Darzalex

Daurismo

Enbrel

Entyvio

Erleada

Farydak

Gazyva

Hemlibra

Ibrance

Idhifa

Ilumya

Inlyta

Inrebic

Isentress

Istodax

Ixempra

Kadcyla

Keytruda

Kyprolis

Lenvima

Litfulo

Lorbrena

Mayzent

Mekinist

Mektovi

Mylotarg

Odomzo

Olumiant

Onureg

Opdivo

Perjeta

Piqray

Pomalyst

Reblozyl

Revlimid

Rituxan

Skyrizi

Stelara

Sutent

Tafinlar

Talzenna

Tarceva

Targretin

Tasigna

Tecentriq

Temodar

Tahlomid

Tykerb

Tymlos

Vidaza

Vizimpro

Votrient

Xalkori

Xtandi

Yervoy

Yonsa

Zeposia

Zykadia

Zinbryta

Rinvoq | BioPlus Specialty Pharmacy | limited distribution

Does Rinvoq have a limited distribution partnership with BioPlus Specialty Pharmacy?

Which health plans does BioPlus Specialty Pharmacy have contracts with?

Does BioPlus Specialty Pharmacy work closely with Rinvoq and AbbVie Inc.?

Does BioPlus Specialty Pharmacy offer services for Rinvoq patients?

What conditions does BioPlus Specialty Pharmacy support?

How does BioPlus Specialty Pharmacy help with insurance?